Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10227302" target="_blank" >RIV/00216208:11110/14:10227302 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/14:00075601 RIV/00216208:11140/14:10227302 RIV/00179906:_____/14:10227302 RIV/00669806:_____/14:10227302 RIV/00064165:_____/14:10227302

Výsledek na webu

<a href="http://www.sciencedierect.com/science/article/pii/S0010865014000125" target="_blank" >http://www.sciencedierect.com/science/article/pii/S0010865014000125</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2014.01.003" target="_blank" >10.1016/j.crvasa.2014.01.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma

Popis výsledku v původním jazyce

To evaluate the safety and efficacy of combined lipid-modifying agents (statin + fenofibrate) in 81 patients (53 males and 28 females) with high or very high cardiovascular risk (according to the SCORE risk chart) and mixed dyslipidemia, which was defined as having 2 of the following 3 lipid abnormalities in mmol/l: LDL-cholesterol (ch) more than 2.5, HDL-ch less than 1 in males and 1,2 in females, triglycerides (TG) more than 1.7. About 44% of those patients had type 2 diabetes mellitus and 30% had impaired fasting glucose. Six-month combined therapy was tolerated very well and reduced LDL-ch by 29%, TG by 40% but HDL-ch increase was noty significant (by 3%). Atherogenic index of plasma: AIP = log(TG/HDL-ch), was decreased significantly in the majority of the patients. It is clear from the study,that more intensive managements of mixed dyslipidemia is needed in those patients.

Název v anglickém jazyce

Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma

Popis výsledku anglicky

To evaluate the safety and efficacy of combined lipid-modifying agents (statin + fenofibrate) in 81 patients (53 males and 28 females) with high or very high cardiovascular risk (according to the SCORE risk chart) and mixed dyslipidemia, which was defined as having 2 of the following 3 lipid abnormalities in mmol/l: LDL-cholesterol (ch) more than 2.5, HDL-ch less than 1 in males and 1,2 in females, triglycerides (TG) more than 1.7. About 44% of those patients had type 2 diabetes mellitus and 30% had impaired fasting glucose. Six-month combined therapy was tolerated very well and reduced LDL-ch by 29%, TG by 40% but HDL-ch increase was noty significant (by 3%). Atherogenic index of plasma: AIP = log(TG/HDL-ch), was decreased significantly in the majority of the patients. It is clear from the study,that more intensive managements of mixed dyslipidemia is needed in those patients.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

56

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

"e133"-"e139"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—